We believe patients deserve an allergen immunotherapy solution which is tailored to their needs and profile and are determined to fully leverage the potential of precision medicine for the benefit of people with allergies.
Pushing the boundaries of science to leverage the potential of precision medicine
Precision medecine consists in using the individual characteristics and mechanism of disease of each patient to evaluate the efficacy and safety of our AIT treatments, while reducing costs both for patients and healthcare authorities.
At Stallergenes Greer, one of the ways we are doing this is by characterising the molecular immunological responses of each patient and exploring molecular diagnostics to identify, with increased precision, the allergens to which each patient is specifically sensitive.
The development of new disciplines and skills are making it possible to specify the diagnosis of respiratory allergy for each individual. Molecular diagnostics provide additional information to guide the prescription and composition of allergen immunotherapy treatments.
Precise personalised allergen immunotherapy solutions
Because each patient presents a unique immunologic profile, we believe that one solution doesn’t fit all. Stallergenes Greer’s approach allows healthcare professionals to create, along with first-line treatments such as allergen eviction and symptomatic medication, a tailored approach that best addresses each individual’s treatments needs.
Stallergenes Greer boasts a longstanding expertise regarding the mechanism of action of AIT and has been intensifying the identification of biomarker candidates to predict and monitor the efficacy of the Group’s AIT treatments. We continue to work towards identifying the most relevant allergens for the treatment of allergies and partner with renowned academics in the field of respiratory allergies to characterise the molecular profiles of allergic patients.
Our research has allowed us to identify pro-allergenic cells, such as Th2A –T helper cells, that are involved in the production of IgE (immunoglobulin E, antibodies produced by the immune system when it reacts to certain substances) as a therapeutic target for AIT.
The development of targeted approaches to patient profiles or the characterisation of specific epitopes, will not only improve disease outcomes for patients but also contribute to a better understanding of both the mechanism of disease and the immunological system response.